Holen Sie sich die Stockscreener-App
0.8226
3.22%
-0.0274
Schlusskurs vom Vortag:
$0.85
Offen:
$0.8245
24-Stunden-Volumen:
122.40K
Relative Volume:
0.27
Marktkapitalisierung:
$7.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+11.31%
1M Leistung:
-48.07%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.8007
$0.85
1-Wochen-Bereich:
$0.67
$0.86
52-Wochen-Spanne:
$0.647
$2.75
Metavia Inc Stock (MTVA) Company Profile
Firmenname
Metavia Inc
Sektor
Branche
Telefon
(857) 702-9600
Adresse
545 CONCORD AVENUE, CAMBRIDGE
Vergleichen Sie MTVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
0.8226 | 7.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
Metavia Inc Aktie (MTVA) Neueste Nachrichten
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa
Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PR Newswire
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa
How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com
RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com
Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com
MetaVia Reports Positive Phase 1 Trial Results - TipRanks
MetaVia (MTVA) Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 - StreetInsider
MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential - marketscreener.com
MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss in Just 26 Days: Phase 1 Trial Reveals Promising Safety Profile - Stock Titan
Stock Market Recap: MetaVia Inc (MTVA) Concludes at 0.74, a 0.64 Surge/Decline - DWinneX
MetaVia’s (MTVA) Buy Rating Reiterated at HC Wainwright - Defense World
MTVA stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada
MTVA stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa
MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… - Zacks Small Cap Research
Korean Dental Association forms election planning team to enhance public oral healthCHOSUNBIZ - Chosunbiz
MetaVia’s obesity drug cuts body weight by 6.3% in 26 days in phase 1 - koreabiomed.com
MetaVia reports positive obesity drug trial results By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com India
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial - marketscreener.com
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Smart Shirt Might Predict Heart Problems - WFMZ.com
MetaVia reports positive obesity drug trial results - Investing.com Australia
MetaVia Announces Positive Phase 1 Trial Results - TipRanks
Metavia Announces Positive Top-Line Data From The 4-Week Phase 1 Mad Trial Of Da-1726 - marketscreener.com
MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726 - TipRanks
MetaVia (MTVA) Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726 - StreetInsider
MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss Without TitrationGame-Changing Trial Results - Stock Titan
Home-Delivered Medical Meals Could Prevent Millions Of Hospitalizations A Year - WFMZ.com
SCHD ETF News, 4/14/2025 - The Globe and Mail
MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon… - Yahoo Finance
MetaVia Inc. Reports Progress in Cardiometabolic Drug Development - MSN
Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView
FY2029 Earnings Forecast for MetaVia Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for MetaVia (NASDAQ:MTVA) - Defense World
Positive Outlook on MetaVia’s Promising Pipeline and Strategic Growth Despite Market Challenges - TipRanks
MetaVia Inc (MTVA) Reports Q4 EPS of -0.59, Revenue at $0 Millio - GuruFocus
MetaVia Inc. (MTVA) reports earnings - Quartz
Bank of England leaves benchmark interest rate unchanged at 4.50% with inflation still high - 69News WFMZ-TV
Stock market today: Wall Street gives back some gains after the Fed extends interest rate pause - WFMZ.com
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PR Newswire
Tonsil Removal Helps Kids With Snoring/Sleep Apnea - 69News WFMZ-TV
New Clot-Busting Drug Quicker And As Effective In Treating Stroke - 69News WFMZ-TV
Finanzdaten der Metavia Inc-Aktie (MTVA)
Es liegen keine Finanzdaten für Metavia Inc (MTVA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):